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Abstract
Background: Antibodies, particularly cytophilic IgG subclasses, with specificity for asexual blood stage antigens of
Plasmodium falciparum, are thought to play an important role in acquired immunity to malaria. Evaluating such responses in
longitudinal sero-epidemiological field studies, allied to increasing knowledge of the immunological mechanisms associated
with anti-malarial protection, will help in the development of malaria vaccines.
Methods and Findings: We conducted a 1-year follow-up study of 305 Senegalese children and identified those resistant or
susceptible to malaria. In retrospective analyses we then compared post-follow-up IgG responses to six asexual-stage
candidate malaria vaccine antigens in groups of individuals with clearly defined clinical and parasitological histories of
infection with P. falciparum. In age-adjusted analyses, children resistant to malaria as well as to high-density parasitemia,
had significantly higher IgG1 responses to GLURP and IgG3 responses to MSP2 than their susceptible counterparts. Among
those resistant to malaria, high anti-MSP1 IgG1 levels were associated with protection against high-density parasitemia. To
assess functional attributes, we used an in vitro parasite growth inhibition assay with purified IgG. Samples from individuals
with high levels of IgG directed to MSP1, MSP2 and AMA1 gave the strongest parasite growth inhibition, but a marked age-
related decline was observed in these effects.
Conclusion: Our data are consistent with the idea that protection against P. falciparum malaria in children depends on
acquisition of a constellation of appropriate, functionally active IgG subclass responses directed to multiple asexual stage
antigens. Our results suggest at least two distinct mechanisms via which antibodies may exert protective effects. Although
declining with age, the growth inhibitory effects of purified IgG measurable in vitro reflected levels of anti-AMA1, -MSP1 and
-MSP2, but not of anti-GLURP IgG. The latter could act on parasite growth via indirect parasiticidal pathways.
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Introduction
IgG antibodies’ pivotal role in anti-malarial protection was
demonstrated by seminal studies involving the passive transfer of
IgG, purified from sera of semi-immune adults, to non-immune
patients resulting in clearance of parasitaemia [1,2,3]. This
protection reflects antibody responses directed to blood stage
antigens of P. falciparum, although the precise mechanism(s)
involved remains unclear. Specific IgG are proposed to have
either a direct [4,5,6] and/or indirect effect [7] on parasite growth
inhibition. Among the IgG subclasses, IgG1 and IgG3 are thought
to play a key role in the protection [8,9]. It is believed that these
subclasses can neutralize parasites directly, by inhibiting parasite
invasion or growth in erythrocytes, or indirectly by a mechanism
involving cooperation between parasite-opsonizing antibodies and
monocytes through binding to the Fcc receptor IIA, leading to
secretion of soluble parasite growth-inhibitory factors such as nitric
oxide or tumor necrosis factor-alpha [7,10,11]. In the latter case
the cytophilic IgG subclasses IgG1 and IgG3 are thought to be of
paramount importance [10,11].
Defining immune surrogates or, even better, correlates of
protection is considered an essential step in the rational develop-
ment of malaria vaccines and sero-epidemiological studies are one
of the valuable tools with which putatively protective anti-malarial
antibody responses can be identified. Here, we present the results of
a sero-epidemiological study in the Niakhar area in Senegal in
PLoS ONE | www.plosone.org 1 October 2009 | Volume 4 | Issue 10 | e7590which parasitological, clinical and epidemiological data were
collected during one-year of close, active follow-up of a large
cohort of children and adolescents. Plasma samples, used for
antibody assessments, were collected from participants at the end of
the study period. The objectives we set were 1) to identify groups of
individuals based on clearly defined differences in their capacity to
control infection and/or disease due to P. falciparum,2 )t o
retrospectively assess the association between anti-malarial protec-
tion and IgG antibody isotype responses to a panel of asexual stage
antigens representing the foremost vaccine candidates, and 3) to use
functional assays of antibody activity in vitro to determine their
predictive value for the results of the sero-epidemiological study.
Materials and Methods
Study site, study design and blood collection
The study took place during the whole of 2003 in Diohine and
Toucar, two villages located 6 km apart in the Niakhar district
situated 135 km south-east of the capital, Dakar. The study area,
study design, and local epidemiology of malaria have been
described in detail elsewhere [12]. Briefly, in this area, malaria is
characteristically seasonal but stable, with an inoculation rate
estimated at 9–12 infective bites per person per year. Transmission
occurs predominantly during the rainy season, between September
and December, and is due exclusively to mosquitoes of the
Anopheles gambiae s.l. complex [13]. The study design included
repeated cross-sectional surveys, to identify sub-clinical parasitae-
mias, conducted in both non-transmission (January, April, June),
and transmission (September, October, December) seasons, when
thick blood smears (TBS) were prepared according to standard
protocols. On the Giemsa-stained TBS, the number of parasites
was counted in 50 high-power fields. The parasite density (PD),
defined as the number of parasites per 100 leucocytes, was then
determined by dividing the mean number of parasites by the mean
number of leucocytes per field. The latter was assessed on 30
standardised microscopic fields. A TBS was declared negative
when no parasites were detected in 200 fields. Active surveillance
to detect malaria attacks was conducted during the transmission
season (September to December 2003). During this period, trained
primary health care personnel visited all study participants twice a
week to check axillary temperature and to assess their clinical
status. To be included in the study, children or young individuals
(less than 20 years old) and their parents had to be present in study
area (Niakhar) during the follow-up. Parents were invited to bring
their child to the dispensary in case of fever at any time. When a
diagnosis of malaria was suspected for any reason and on any
occasion, a TBS was performed and a questionnaire related to
clinical signs completed. Individuals were given anti-malarial
therapy according to the recommendations of the Senegalese
National Control Program for malaria at that time (i.e. first-line
treatment with chloroquine). After the transmission season and at
the end of the one-year parasitological and clinical follow-up
(December 2003), plasma samples were isolated from venous
blood collected from 305 individuals aged 7 to 19 years old.
The study was explained in detail to all participants and their
parents, and either they or their parents gave their signed
informed consent. The ethics committee of the Health Ministry of
Senegal approved the study protocol (Nu000526/MS/DERF/
DER).
Segregation of children according to malariometric data
Uncomplicated malaria attack (UMA) group. We defined
uncomplicated malaria attacks (UMA) as the association of an
axillary temperature greater than 37.5uC with a PD equal to or
higher than 2,500/ml and with no other apparent cause of fever, in
order to avoid potential bias. Any individual identified as having
had at least one UMA during the follow-up period was included in
the UMA group.
Asymptomatic carriage (AC) groups. Individuals with no
UMA during the follow-up and with at least one parasite-positive
TBS were considered as asymptomatic carriers (AC). All TBS
performed in the 15 day period immediately following anti-
malarial treatment were excluded when assessing the study
participants’ parasitological phenotype. The AC group was
further segregated according to their levels of parasitaemia (low
vs high). As a UMA was defined as the association of fever with a
parasite density equal to or higher than 2500/ml, we selected the
same threshold to discriminate between two AC groups. The AC
group with low parasitaemia (ACLP) group thus comprised
individuals who had at least one parasite-positive TBS but with
a PD below 2,500/ml on each occasion. The AC group with high
parasitaemia (ACHP) comprised individuals who had at least one
positive TBS during the follow-up but with a PD equal to or above
2,500/ml on at least one of the parasite-positive TBS. This sub-
segregation was designed to allow evaluation of antibody
response(s) potentially associated with anti-parasite (ACLP vs
ACHP groups), anti-disease (ACHP vs UMA groups) and/or
combined anti-parasitic/anti-disease (ACLP vs UMA groups).
Uninfected individuals. Children with no UMA during the
active follow-up and no P. falciparum parasites on any of their six
TBS could be considered to either be completely protected or
simply not exposed to infection. To avoid possible confounding we
excluded all such individuals (n=33) from all analyses.
Antibody measurements and HBB AS genotype
An Enzyme-Linked Immuno-Sorbent Assay (ELISA) following
a standardized methodology described in the Afro-immunoassay
network standard operating procedure (procedure number AIA-
001-02) was used to assess the antibody response, at the end of the
follow-up (December 2003), to the following panel of recombinant
proteins derived from sequences of asexual stage antigens of P.
falciparum:
1. MSP119 20–43, 1615–1723/Uganda-Palo-Alto strain
2. MSP2/3D7 & MSP2/FC27
3. MSP3 161–276/FC27 strain
4. AMA1 25–545/FVO strain
5. GLURP 25–514/F32 strain
MSP119 (Pasteur Institute, Paris, France) was expressed in a
Baculovirus/insect cell system [14], AMA1 (Biomedical Primate
Research Centre, Rijswijk, The Netherlands) in Pichia pastorius
[15], and MSP2/3D7, MSP2/FC27 (both La Trobe University,
Melbourne, Australia), MSP-3 and GLURP R0 (both Statens
Serum Institute, Copenhagen, Denmark) all in Escherichia coli [16].
ELISA plates were coated with 100 ml of recombinant protein
solutions (1X PBS) at a final concentration of 1 mg/ml. 150 mlo f
blocking buffer (3% milkpowder in PBS - 0.1% Tween 20) was
added and kept at room temperature for 1 hour. Plasma samples
were diluted in dilution buffer (1% milk powder in 1X PBS 0.1%
Tween 20, 0.02% NaAz) 1:200 for total IgG (IgGt) and 1:50 for
IgG1, IgG2, IgG3 and IgG4 for all recombinant proteins except
for AMA1 for which dilutions used were: 1:2000 (IgGt) and 1:500
(IgG1, IgG2, IgG3 and IgG4). The monoclonal antibodies used
for determination of the immunoglobulin isotypes were mouse
anti-IgG1 (clone NL16, Skybio), anti-IgG2 (clone HP 6002,
Sigma), anti-IgG3 (clone ZG4, Skybio) and anti-IgG4 (clone RJ4,
Skybio). Two polyclonal antibodies conjugated to HRPO were
IgG and Malaria Protection
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IgG and a goat anti-mouse IgG (H+L) (Catltag) diluted 1:2000 for
IgG1, 1:5000 IgG2 and IgG3, and 1:3000 for IgG4. Bound
enzyme was detected with TMB and the reaction was stopped with
0.2 M H2SO4 (100 ml/well). Plates were extensively washed
between each incubation period with PBS Tween-20 (0.1%) NaCl
(0.5 M). The optical density (OD) was read at 450 nm (reference
filter 620 nm). Positive-control plasma samples from Gabonese
individuals and negative-control plasma samples from Dutch
individuals were included in each plate and results were expressed
in arbitrary units (AU) calculated from the formula: 1006[ln(OD
test plasma)2ln(OD negative control plasma)]/[ln(OD positive
control plasma)2ln(OD negative control plasma)] [17]. The
positivity thresholds were determined from the mean reactivities
+2 SD of 30 plasma samples from Dutch non-immune volunteers.
Since it is known that antibodies of the IgG2 and IgG4 isotypes
with specificity for the asexual stage antigens assessed here are
generally present at lower prevalence and intensity compared with
cytophilic isotypes, they were quantified, in a first step, on a sub-set
of 42 samples. If the proportion of responders among these samples,
for either isotype, was .30% (an arbitrarily chosen threshold), we
proceeded to determine the corresponding responses in samples
from the whole study population.
Previous studies have shown that carriage of the sickle cell
trait is associated with protection against uncomplicated malaria
and with the modulation of anti-parasite antibody responses
[18,19,20,21,22], therefore all the individuals carrying the HBB
AS genotype (n=32) were excluded from analyses that compared
antibody responses between groups. The determination of the
different HBB genotypes was performed by PCR/RFLP as
previously described [23].
Antibody purification for functional assay
Thirty plasma samples, matched according to age, gender and
area of residence, were randomly selected from each of the ACLP,
ACHP and UMA groups. IgG was purified from 600 ml of each of
these plasma samples using SpinTrap Protein G columns (GE,
Eindhoven, The Netherlands) using procedures recommended by
the manufacturer. The purified IgG samples were concentrated
using Vivaspin 20 ultrafiltration spin columns (Sartorius, Palai-
seau, France) according to the recommended protocol to a final
concentration of at least 20 mg/ml and the concentrated IgG were
then filter-sterilized using 0.22 mm centrifuge filters (Millipore,
Carrigtwohill, Ireland). The IgG were quantified using the
NanoDropH ND-1000 spectrophotometer and the required IgG
concentration for the parasite growth assay (20 mg/ml) was
obtained through appropriate dilution in RPMI 1640 medium
before each functional assay.
Parasite Growth Inhibition Assay
Parasite Growth Inhibition (PGI) was performed as previously
described with minor modification [24]. Briefly, 3D7 strain P.
falciparum parasites maintained in culture in vitro were synchronized
using alanine treatment and collected for use at the beginning of
schizogony. Assays were initiated in flat-bottomed 96-well tissue
culture plates with a starting parasitaemia of 0.3% in a final
volume of 100 ml containing 10% normal human serum, 20 mg/
ml of gentamicin, a final concentration of test IgG of 10 mg/ml
(50 ml of the 20 mg/ml IgG preparation) at a haematocrit of 2% in
RPMI 1640. The growth inhibitory capacity of each sample was
assayed in triplicate and each assay plate included positive
(purified rabbit anti-AMA1 IgG) and negative control samples
(RBC alone and parasite culture without IgG). Assays were
collected for analysis 42–44 h after initiation and the PGI in the
presence of IgG was assessed by measuring the Plasmodium lactate
dehydrogenase levels in parasite cultures [25]. The PGI was
calculated as follows: % PGI~ 1{ OD IgG sample OD RBC ð ð ð
controlÞ= OD schizont control{OD RBC control ð ÞÞÞ   100:
Statistical analyses
The association of specific IgG responses with anti-malarial
protection was first assessed using a linear model (ANCOVA)
taking into account the age effect on the IgG levels. The
comparison of IgG levels between the UMA and AC groups was
performed to investigate the potential anti-malarial protective
responses and the comparison of the IgG levels between the UMA
vs ACHP, ACHP vs ACLP, UMA vs ACLP groups aimed to
identify more precisely anti-parasite and/or anti-malarial (clinical)
protective responses.
Logistic regression was applied for the analysis of associations
with protection against malaria attacks (UMA vs AC groups) which
was used as the dependent variable against the explanatory
variables (IgG responses/age) shown to be associated byANCOVA.
This approach allowed for assessment of the independence of
associations of IgG responses with protection in the linear model
and to additionally check for the presence or absence of interactions
between putatively protective IgG responses. The relationship
between the number of antigens recognized at high titre by each
individual and group (UMA, ACHP and ACLP) was also
investigated using logistic regression. For this purpose, antibody
titres (IgGt responses to AMA1 and MSP1, IgG3 to MSP3 and
MSP2 [average of responses to the FC27 and 3D7 alleles], and
IgG1 to GLURP) in the whole study population were re-coded into
tertiles and values in the top tertile were considered a high response
for each specific antigen. Next, the number of high responses was
calculated per individual. Logistic regression was then performed
with group (UMA, ACHP and ACLP) as outcome and age and
numberofantigensrecognizedathightitreasexplanatoryvariables.
The non-parametric Kruskal Wallis and Mann-Whitney tests
were used to test for differences in levels of PGI and antibody
levels between the different groups. All analyses were carried out
in STATA version 8 (StataCorp, College Station, TX).
Results
Demographic and other characteristics of study
participants
Details of the study participants are presented in Table 1. Their
mean age was 11.8 years and the sex ratio (female:male) was
0.68. 178 were inhabitants of Diohine and the other 127 were
from Toucar. The mean age of those in whom one or more
uncomplicated malaria attacks (UMA group) were detected was
significantly lower than that of those in whom asymptomatic
carriage of parasites (AC group) was detected, while the gender
and village distribution of the two groups was similar (Table 1).
HBB AS carriers were significantly less frequent in the UMA
compared to the AC group. After exclusion of those with HBB AS,
the UMA group for analyses comprised 89 children among whom
64, 21 and 4, had had, respectively, 1, 2 and 3 malaria attacks
during the follow-up period. The AC group for analyses comprised
157 children (with sub-groups defined thus: 89 asymptomatic
carriage with low parasitemia [,2500/ul, ACLP] & 68 asymp-
tomatic carriage with high parasitemia [$2500/ul, ACHP]).
Antibody profiles
A high proportion of the study participants had IgG responses
to all recombinant proteins. Cytophilic IgG1 and IgG3 isotype-
specific responses were most frequent, with prevalences ranging
IgG and Malaria Protection
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3D7)(Fig. 1). IgG1 and IgG3 responses segregated according to
study participants’ clinical/parasitological history are presented in
Figure 2. In general, regardless of the antigen or IgG isotype, the
lowest responses were observed in the UMA group. A number of
potentially confounding factors were assessed: (i) P. falciparum
parasitemia at the time of the blood draw in December 2003 (47%
were carrying infections, as determined by microscopical exam-
ination of blood smears) did not significantly influence the level of
IgG responses (data not shown); (ii) the proximity of malaria
episodes to blood draws in the UMA group (2 individuals had a
malaria episode in December, 13 in November) did not affect
antibody levels (data not shown). Age had an effect on the levels of
specific antibody responses, most of which increased with age.
Particularly notable was IgG1 with specificity for GLURP and
IgGt with specificity for MSP2 FC27 (Fig. 3). Given that it
was clearly related with antibody levels, we included age as a
continuous variable in all linear analyses.
Protection against malaria
The putative protection against uncomplicated P. falciparum
malaria conferred by carriage of HBB AS [26] was confirmed here
(Table 1), showing that our study had sufficient statistical power to
detect the effects of factors that have proven associations with anti-
malarial immunity. In order to investigate potential associations
between antibody responses and protection against malaria
attacks, we therefore first used a linear model (Analysis of
covariance (ANCOVA)) to compare the levels of specific IgG
between the UMA and unsegregated AC groups (Table 2). This
analysis revealed that the levels of IgG3 directed to either of the
MSP2 antigens (FC27 and 3D7 allelic forms) and the levels of
IgG1 directed to GLURP were significantly higher in the AC
compared to the UMA group (Table 2). Furthermore, a similar
trend, but of only borderline significance, was found for IgG3 with
specificity for GLURP. No such associations were observed for
IgG responses to either AMA1, MSP1 or MSP3.
The logistic regression model confirmed the apparent anti-
malarial protective effects of the IgG isotype responses identified
by ANCOVA. Thus, the levels of IgG3 with specificity for MSP2
3D7, and of IgG1 with specificity for GLURP were both shown to
be significantly higher in the AC versus UMA groups, while a
similar trend, but of borderline significance, was found for IgG3
directed to the FC27 allele of MSP2. Independently of the IgG
activity, age (p=0.034, OR=0.89) also differed significantly
betweenthegroups.Possibleinteractionsbetweenthe three antibody
responses were investigated to determine potential combination
effects. No interaction was observed in the logistic regression model,
indicating that the three responses act independently, and, possibly,
additively.
Protection against disease and/or parasitaemia
The sub-segregation of the AC group (ACHP and ACLP) was
designed to allow for assessments of possible associations between
specific IgG responses and different aspects of acquired immunity.
The comparison of IgG levels between the ACHP and UMA
groups, respectively resistant and susceptible to the clinical
symptoms associated with P. falciparum infection, thus aimed to
determine whether an ‘anti-disease’ type of immunity was
associated with any of the antibody activity measured here. By
ANCOVA, the levels of IgGt to both MSP2 (3D7 allelic form) and
to GLURP, of IgG1 to GLURP and of IgG3 to MSP2 (both allelic
forms) were found to be higher in the ACHP compared to the
UMA group (Table 3), but after multiple test adjustments none of
these associations remained statistically significant, and further
logistic regression analysis was therefore not performed.
Associations between antibody responses and protection against
higher-grade parasitemia were assessed through comparison of
IgG levels in the ACHP and ACLP. Here, the levels of IgGt
directed to GLURP, of IgG1 to MSP1 and of IgG3 to both MSP2
(FC27 allelic form) and MSP3 were higher in the ACLP compared
to the ACHP group (Table 3). Again, however, after multiple test
adjustments only the difference in IgG1 to MSP1 remained with
borderline statistical significance, and logistic regression was
therefore not conducted.
The association between specific antibodies and the combined
ability to protect against disease and high-grade parasitemia was
assessed through comparison of the IgG levels in the ACLP and
UMA groups. This analysis showed that the levels of IgGt directed
to MSP1, to MSP2 (both allelic forms) and to GLURP, as well as
of IgG1 to MSP1 and to GLURP and of IgG3 to both MSP2 (both
allelic forms) and to GLURP were all higher in the ACLP
compared with the UMA group. After multiple test adjustments,
the higher levels of IgGt and of IgG1 to GLURP and of IgG3 to
MSP2 (FC27 allelic form) remained statistically significantly
different between the groups (Table 3). In the logistic regression
model, the levels of IgG1 with specificity for GLURP (p=0.035;
Table 1. Participants’ characteristics.
n Age* Gender** Villages*** RBC defect
(Range, IQRs) Female/Male Diohine/Toucar HBB AS carriers****
Whole population 305 11.8 (7–19, 9–14) 123/182 178/127 32
Groups{
UMA 94 10.9 (7–18, 9–12) 36/58 53/41 5
AC 178 12.0 (7–19, 10–14) 70/108 114/64 21
ACHP 74 11.5 (7–19, 9–14) 31/43 51/23 6
ACLP 104 12.4 (7–17, 11–14) 39/65 63/41 15
UMA=uncomplicated malaria group; AC=asymptomatic carrier group; ACHP=asymptomatic carrier subgroup with high parasitemia; ACLP=asymptomatic carrier
subgroup with low parasitemia; RBC=red blood cells.
*Significant age difference between UMA, AC and uninfected groups (Anova, p,0.0001).
**No significant gender difference in the groups (Chi2, p=0.513).
***No significant difference between groups (Chi2, p=0.25).
****The Hbb AS genotype was significantly less frequent in the UMA group than the group of individuals free of clinical malaria (Chi2, p=0.049).
{Excludes the uninfected group (33 individuals).
doi:10.1371/journal.pone.0007590.t001
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excluded) with specificity for the panel of asexual blood stage antigens of P. falciparum. Box-whisker plots represent medians with 25
th and 75
th
percentiles (boxes), and with 10
th and 90
th percentiles (whiskers), outliers as discrete dots. The prevalence of positive responders to each recombinant
proteins is noticed between brackets. A positive responder was defined as an individual who had a level of specific IgG over the positivity thresholds.
These positivity thresholds were determined, for total IgG, IgG1 and IgG3 to each recombinant proteins, from the mean reactivities+2S Do f3 0
plasma samples from Dutch non-immune volunteers.
doi:10.1371/journal.pone.0007590.g001
Figure 2. IgG antibody isotype responses in groups of children with and without malaria attacks. IgG1 (A) and IgG3 (B) responses to a
panel of recombinant proteins corresponding to 5 different P. falciparum asexual stage antigens in groups of children segregated according to their
status as either low (ACLP, ,2500 parasites/ul) or high (ACHP, $2500 parasites/ul) asymptomatic parasitemia carriers, or those with one or more
malaria attacks (UMA, parasitemia plus fever) during 12 months’ follow-up. Box-whisker plots represent medians with 25
th and 75
th percentiles
(boxes), and with 10
th and 90
th percentiles (whiskers), outliers as discrete dots.
doi:10.1371/journal.pone.0007590.g002
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(p=0.004; OR=0.72) in the ACLP group were shown to be
statistically significantly higher than those in the UMA group.
Further analyses revealed no interaction between these two
putatively protective IgG responses in the logistic regression
model. Separately, and independently of the IgG associations
described above, age was also found to be significantly higher in
the ACLP group (p=0.011; OR=0.84).
Study participants’ cumulated antibody-mediated recognition of
multiple antigens at high levelswas also found, independently of age,
to be associated with the outcome of infection with P. falciparum.
Here, logistic regression analyses revealed 3.6-fold greater odds
(p=0.0003) of being in the ACLP group versus the UMA group
whenresponding strongly to 2 ormoreantigens,and 2.4-foldgreater
odds (p=0.019) of an individual being inthe ACLP groupversus the
ACHP group when responding strongly to 3 or more antigens.
Parasite growth inhibitory properties of IgG
The PGI of the matched (according to age, gender and area of
residence) samples selected from the UMA, ACHP and ACLP
groups did not differ significantly (Fig. 4), although the ACLP
group had the highest mean level of PGI (48.4%), the ACHP
group slightly lower (46.5%) and the UMA group the lowest
(39.0%). In addition, the level of PGI decreased significantly as a
function of increasing age (Fig. 5).
In further analyses, ELISA-detectable antibody levels in the
original plasma were compared in the same set of samples
segregated according to their PGI activity: a ‘high’ group (36
individuals) with PGI.50%, and a ‘low’ group (47 individuals) with
PGI#50%. The group with high PGI activity had, after correction
for multiple comparisons, significantly higher levels of IgGt directed
to MSP1 and to MSP2 (both allelic forms) than those with low PGI
activity. Among the cytophilic subclasses, elevated IgG1 responses
to MSP1 and IgG3 responses to MSP2 (both allelic forms) were
associatedwithahighercapacitytoinhibitparasitegrowth(Table4).
Anti-AMA1 IgG antibody responses were not associated with anti-
malarial protection in the analyses of sero-epidemiological data,
however significantly higher levels of total anti-AMA1 IgG, and
particularly of anti-AMA1 IgG1 antibodies, were found in those
with higher PGI capacity (Table 4).
Figure 3. Age-dependent changes in antibody responses. Graph was performed with the regression fit command of Stata software. The age
effect on IgGt to MSP2 FC27 and IgG1 to GLURP was significant (ANCOVA, table 3, ACLP vs UMA, p=0,046 and p=0,047 respectively).
doi:10.1371/journal.pone.0007590.g003
Table 2. Associations between IgG responses and protection against malaria attacks.
Linear model (ANCOVA)** Logistic regression{
IgG responses* Status IgG mean (AU) Coefficient P CI P OR
MSP2 3D7 IgGt UMA/AC 105.34/112.88 7.25 0.005 [2.19–12.31]
MSP2 3D7 IgG3 UMA/AC 95.13/100.25 5.14 ,0.0001*** [2.51–7.75] 0.049 0.70
MSP2 FC27 IgGt UMA/AC 79.88/93.61 12.56 0.002 [4.60–20.53]
MSP2 FC27 IgG3 UMA/AC 80.15/90.14 9.37 ,0.0001*** [4.78–13.95] 0.076 0.84
GLURP IgGt UMA/AC 72.44/91.44 16.99 ,0.0001*** [7.84–26.15]
GLURP IgG1 UMA/AC 80.45/100.54 17.64 ,0.0001*** [7.83–27.45] 0.024 0.91
GLURP IgG3 UMA/AC 59.47/77.73 16.28 0.003 [5.49–27.08]
*Presented are only those antibody responses, from the 20 tested, found to be significantly associated with malariometric status (P,0.05 before multiple test
correction); IgGt: total IgG.
**The effect of malariometric status on IgG responses, determined by ANCOVA, was adjusted for age.
***Significantly different after adjustment for multiple tests (Bonferroni correction, threshold of significance: P=0.002).
{Logistic regression was used to assess associations with protection against malaria attacks, where status (UMA vs AC groups) was used as the dependent variable
against the explanatory variables (IgG subtype responses/age) shown to be significantly associated by ANCOVA. OR values were assessed for 10 AU increased.
Note: age was also independently associated with malaria protection in this analysis (P=0.034, OR=0.89).
doi:10.1371/journal.pone.0007590.t002
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In this study we used retrospective analyses to assess the
associations between parasite-specific antibody activity and
protection from malaria and/or high grade parasitaemia.
Although therefore differing in design from more commonly-used
prospective studies, precluding direct comparison of results, our
findings do support the continued development of vaccines based
on specific P. falciparum asexual stage antigens. A distinguishing
feature of our study is that we combined quantification of IgG
subclass responses to a panel of P. falciparum vaccine candidate
antigens with determinations of functional antibody activity using
purified IgG in a standardized in vitro assay of P. falciparum asexual
stage growth inhibition. In addition, the continuous and close
active surveillance of study participants we conducted over 1 year
allowed for precise definitions of their clinical and parasitological
phenotypes. The study therefore had sufficient power, using
adjusted analyses where appropriate, to identify independent
associations between anti-malarial protection and defined anti-
body responses. Of equal importance, we feel, is the fact that our
findings emphasize the need to identify IgG subclass-specific
responses in sero-epidemiological studies of this kind rather than
simply total IgG.
Our data show that naturally-acquired clinical and parasitolog-
ical immunity in children living in an area characterized by stable,
highly seasonal transmission of P. falciparum malaria is associated
specifically with (i) cytophilic IgG1 and IgG3 responses (the latter
of borderline significance) to GLURP and (ii) IgG3 responses
to MSP2, measured after the transmission season. We found,
furthermore, an association of borderline significance between
anti-parasite immunity and higher levels of IgG1 directed to
MSP1. All of these associations, importantly, were independent
both of each other and of age. The possible functional attributes in
vivo of both the anti-MSP1 and -MSP2 responses were further
emphasized by their associations with enhanced inhibition of
parasite growth by purified IgG in vitro.
Despite their evident design differences, then, the results of our
retrospective study are nevertheless consistent with those of other
prospective sero-epidemiological studies that have shown associa-
tions between anti-malarial protection and IgG responses directed
to either the GLURP R0 domain [27,28,29,30,31,32] or to MSP2
[20,28,33,34,35,36,37,38], although two very recent studies could
not confirm all those findings [39,40]. The reasons for discordant
observations could be numerous, and most likely include specific
differences in either technical aspects or study design, but we favor
malaria transmission patterns, and thus primarily cumulative
variations in the degree of exposure to particular antigens, as
probably the strongest influence on outcomes [9]. One other recent
study is notable in this context, since it reports findings that are in
marked contrast to those of our own and others’ [40]. That study,
involving a Senegalese village population, reported that anti-MSP3
IgG3 responses alone - and none of the responses to any of the other
antigens tested, including those assessed in the study presented here
- wereassociated with anti-malarial protection. It should be stressed,
however, that malaria in the area of that particular study village is
both holoendemic and perennially transmitted, thus clearly
distinguishing it from most other studies [40]. A recent Kenyan
study also identified anti-MSP3 IgG responses as being strongly
Table 3. Associations between IgG responses and anti-disease/anti-parasite immunity.
ANCOVA* Logistic regression***
Status
IgG responses Status IgG mean (UA) Coefficient P CI P OR
IgGt to MSP2 3D7 UMA/ACHP 105.34/112.48 7.04 0.039 [0.34–13.74]
IgG3 to MSP2 3D7 95.13/100.03 4.93 0.008 [1.30–8.54]
IgG3 to MSP2 FC27 80.15/86.63 6.56 0.033 [0.52–12.60]
IgGt to GLURP 72.44/85.39 12.05 0.040 [0.53–23.57]
IgG1to GLURP 80.45/97.29 15.52 0.014 [3.17–27.87]
IgG1 to MSP1 ACHP/ACLP 73.67/85.30 10.36 0.007 [2.93–17.78]
IgG3 to MSP2 FC27 86.63/92.82 5.89 0.015 [1.14–10.64]
IgG3 to MSP3 65.92/75.31 8.70 0.037 [0.52–16.87]
IgGt to GLURP 85.39/96.07 8.70 0.037 [0.52–16.87]
IgGt to MSP1 UMA/ACLP 73.97/84.56 9.18 0.045 [0.20–18.15]
IgG1 to MSP1 74.48/85.30 9.84 0.014 [2.00–17.68]
IgGt to MSP2 3D7 105.34/113.19 7.61 0.017 [1.35–13.85]
IgG3 to MSP2 3D7 95.13/100.41 5.24 0.002 [1.89–8.59]
IgGt to MSP2 FC27 79.88/97.56 14.89 0.002 [5.69–24.08]
IgG3 to MSP2 FC27 80.15/92.82 11.07 ,0.0001** [5.76–16.39] 0.004 0.72
IgGt to GLURP 72.44/96.07 21.58 ,0.0001** [11.14–32.02]
IgG1 to GLURP 80.45/103.04 19.25 0.001** [8.09–30.39] 0.035 0.90
IgG3 to GLURP 59.47/82.20 20.43 0.002 [7.74–33.13]
*The effect of malariometric status on IgG responses (IgGt: total IgG), determined by ANCOVA, was adjusted for age.
**Significantly different after adjustment for multiple tests (Bonferroni correction, threshold of significance: P=0.002).
***Logistic regression was applied for the analysis of associations with protection against malaria attacks, where status (UMA vs ACLP groups) was used as the
dependent variable against the explanatory variables (IgG subtype responses (IgG3 to MSP2 FC27 and IgG1 to GLURP) and age) shown to be significantly associated
by ANCOVA. OR values were assessed for 10 AU increased. Age was also associated with malaria protection in the analysis (p=0.011, OR=0.84).
doi:10.1371/journal.pone.0007590.t003
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purified from a total of 75 plasma samples is illustrated for groups of children segregated according to their status as either low (ACLP,
,2500 parasites/ul) or high (ACHP, $2500 parasites/ul) asymptomatic parasitemia carriers, or those with one or more malaria attacks (UMA,
parasitemia plus fever) during 12 months’ follow-up. 15 samples (5 matched trios) were excluded due to large variations between triplicate samples
(coefficient of variation .30%). Box-whisker plots represent medians with 25
th and 75
th percentiles (boxes), and with 10
th and 90
th percentiles
(whiskers), outliers as discrete dots. Doted lines represent the arithmetic mean of parasite growth inhibition.
doi:10.1371/journal.pone.0007590.g004
Figure 5. The association between parasite growth inhibitory activity of purified IgG and age. Parasite growth inhibitory (PGI) capacity of
purified IgG plotted against age, with regression line fitted (using the regression fit command of STATA software). A significant difference in PGI
(p=0.03, Kruskall-Wallis test) was observed between groups segregated according to age (8–9 years vs 10–11 years vs 12–14 years).
doi:10.1371/journal.pone.0007590.g005
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with distinctly different exposure to malaria compared to our own
cohort [35]. We employed the same operating procedures (i.e.
standardized protocols developed by the AfroImmunoAssay
consortium) with a panel of antigens similar to that used by Nebie ´
and colleagues in their study of Burkinabe children [31]. Malaria
transmission in their study area is very similar to that in ours, and
the studies were conducted in the same year (2003). Their findings
may thus plausibly be compared directly with our own. They
reported significant associations with anti-malarial protection for
anti-GLURP (IgG3) and anti-AMA1 (IgG1) responses, but no such
associations for either anti-MSP1 or -MSP3 IgG, while anti-MSP2
IgG responses were not assessed [31]. Although clearly not identical
the broad similarities of the findings of the two studies are
nevertheless striking, and indeed lend credence to GLURP’s
vaccine candidacy. The different outcome for anti-AMA1 IgG
may reflect the inclusion of Burkinabe below 4 years of age, since
seroconversion to AMA1 occurs substantially earlier in life than for
other antigens, and responses to the latter may mask any effects of
anti-AMA1 IgG in older individuals. On the other hand, another
recentstudy that includedchildrenofa similar age-range toours did
identify associations between anti-malarial protection and anti-
AMA1 IgG3, albeit in Papua New Guineans [41]. No plausible
explanation is immediately obvious for the difference between the
findings of the latter study and our own. Transmission-related
differences may be important, possibly including the unknown
effects of exposure to both P. falciparum and P. vivax.
The accurate phenotypic segregation of our study participants
allowed us to identify IgG responses with putatively varying
functional attributes. Anti-parasite activity appeared to be partic-
ularly associated with IgG1 directed to MSP1, since the magnitude
of this response distinguished those (the ACLP group) able to
control parasitemia above a defined threshold from those (the
ACHP group) that could not. This finding is consistent with the
results of other sero-epidemiological studies of this molecule, some
of which also identified an association of anti-MSP1 IgG with
control of high-grade parasitaemia [39,42,43,44,45,46]. As men-
tionedabove,ourobservationofstrongerparasitegrowthinhibitory
activity in vitro in samples containing the highest levels of anti-MSP1
IgG1 lend strong support to the notion that such antibodies indeed
have a functional role in vivo. Although displaying only non-
significant trends, differences in the levels of anti-MSP2 IgG3
suggested some degree of association with clinical immunity (UMA
vs ACHP groups, Table 3), but, more plausibly, when assessing the
sero-epidemiological together with the functional in vitro findings,
these antibodies appear to confer substantial protection against
high parasitaemia. A logical conclusion would therefore be that
cytophilicanti-MSP1 and anti-MSP2 IgGfunction inan additiveor
even synergistic way to prevent parasite multiplication.
We observed markedly contrasting associations for IgG respons-
es directed to GLURP compared with those directed to AMA1. On
the one hand, the sero-epidemiological analyses revealed that
cytophilic anti-GLURP IgG activity was strongly associated with
anti-malarial protection (Tables 2 & 3), but this was not the case for
anti-AMA1 IgG, while higher levels of the latter antibodies were
associated with functional activity in vitro but no such association
was detectable for anti-GLURP IgG (Table 4). It is known that IgG
responses to AMA1 are acquired rapidly in early life, as mentioned
above, and most sero-epidemiological studies that have revealed
anti-malarial protective associations for anti-AMA1 IgG have
included children below the age range of those in our study,
possibly, therefore, offering an explanation for the different
outcomes [28,31,35,38,41]. For GLURP, pre-existing knowledge
suggests an explanation for the apparent lack of anti-GLURP IgG
activity in the functional assay. This explanation rests on the
proposed mechanism of cooperation between monocytes and
cytophilic IgG in mediating parasite growth inhibition [2,7], and
the evidencefor a functionalroleofanti-GLURP antibodiesin such
a process [47,48]. Our own preliminary data show appreciable (up
to 52%) monocyte-mediated parasite growth inhibition by affinity-
purified anti-GLURP R0 antibodies derived from a pool of six
plasma samples with high IgG responses against GLURP R0
randomly selected from children in the study described here (D.
Courtin & M. Theisen, unpublished observations). Anti-GLURP
antibodies thus seem not to exhibit the type of direct anti-parasite
effects that the growth inhibition assay used here aims to quantify,
but rather act indirectly through opsonic interactions with
merozoites and monocytes.
Finally, some aspects of the growth inhibition assay employed
here are worthy of mention. Despite using purified IgG -
effectively precluding any influence of anti-malarial metabolites
or other potentially parasitistatic molecules in the in vitro assay - we
did not find significant differences in functional activity between
the groups segregated on the basis of clinical and parasitological
phenotypes. This is in line with the results of studies that used
either dialysed or whole serum rather than purified IgG, but that
nevertheless found no association between the amounts of growth-
inhibitory antibodies detectable in vitro and reduced risk of malaria
[49,50,51], but contrasts with those of another recent study from
Kenya [52]. Whether the outcome in this context was affected by
our use of a standard concentration (10 mg/ml) of IgG - well
Table 4. Comparison of IgG levels in groups of samples with
high or low parasite growth inhibition (PGI).
PGI#50%*(n=47) PGI.50% (n=36) P**
IgG
responses
Median of Ab responses in arbitrary units
(5–95 percentile)
MSP1
IgGt 64.74 (3.72–110.13) 96.34 (29.41–112.93) 0.0005***
IgG1 65.65 (8.71–101.60) 97.73 (42.48–103.93) 0.0005***
MSP2 FC27
IgGt 66.18 (12.90–114.07) 95.08 (38.04–136.91) 0.0015***
IgG3 72.11 (37.76–101.99) 90.46 (50.83–105.28) 0.0043
MSP2 3D7
IgGt 108.56 (65.98–124.65) 118.92 (67.33–131.88) 0.0005***
IgG3 99.43 (64.40–105.12) 102.77 (79.83–108.13) 0.0086
MSP3
IgGt 44.58 (0–100.31) 44.47 (0–99.94) 0.33
IgG3 66.51 (21.25–101.73) 64.64 (26.08–101.33) 0.77
GLURP
IgGt 70.42 (4.91–135.36) 78.09 (23.27–135.14) 0.03
IgG1 76.79 (3.81–141.86) 97.97 (29.54–145.74) 0.04
IgG3 51.55 (0–131.74) 81.50 (0–132.37) 0.07
AMA1
IgGt 89.86 (33.77–109.02) 104.50 (93.87–110.44) 0.0001***
IgG1 88.23 (13.67–103.28) 100.51 (89.25–104.91) 0.002***
*No significant difference in age was observed between the groups of samples
showing high and low level of PGI (p=0.33, Mann-Whitney).
**Non parametric Mann-Whitney test was used to compare IgG levels in the
groups.
***Significant p value after multiple test adjustment (Bonferroni correction).
doi:10.1371/journal.pone.0007590.t004
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the assay procedure we adopted is not known. One consistent
finding in this and the other recently published studies that have
used a broadly comparable in vitro assay concerns the age-related
decline in growth inhibitory activity [50,52]. The explanation for
this inverse association remains obscure, but one implication is
that the naturally-acquired protection enjoyed by older age-groups
relies on alternative parasite growth inhibitory mechanisms. In any
case these findings serve to reiterate the need for development and
standardization of adequate and appropriate in vitro assays that
faithfully reflect in vivo antibody function.
In summary, the results of this study clearly highlight the role of
IgG antibody subclass responses in acquired anti-malarial
immunity. On the basis of the data presented, we conclude that
naturally-acquired immunity to malaria, in the setting described,
relies on the presence of a constellation of cytophilic IgG
antibodies, displaying differing specificities and probably having
disparate functional attributes, but that may operate in concert in
vivo to suppress parasitaemia to levels below those causing disease.
We interpret the results as providing strong support for the
development of a vaccine designed to elicit antibody responses
simultaneously to multiple asexual stage antigens of P. falciparum.
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